Roche Reports Two-Year VIALE-A Data for Venetoclax Plus Azacitidine in AML

Roche today presented two-year overall survival data from the Phase 3 VIALE-A trial evaluating venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy. The data showed that the overall survival benefit of venetoclax was maintained at two years, with 37% of patients in the venetoclax arm alive at two years compared to 17% in the placebo arm.